What it's for (Indications)
- Amiodarone is a highly effective antiarrhythmic agent primarily indicated for the treatment of life-threatening recurrent ventricular arrhythmias, such as recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT), that have not responded to other antiarrhythmic therapies or where other therapies are not tolerated.
- Its use in these severe conditions is justified by its significant efficacy despite its considerable toxicity profile.
- While primarily approved for ventricular arrhythmias, it is also frequently used off-label for the management of refractory supraventricular arrhythmias, including atrial fibrillation and atrial flutter, particularly in patients with structural heart disease or when other agents have failed.
- The decision to initiate amiodarone therapy necessitates careful consideration of its potential benefits against its numerous and often serious adverse effects, requiring diligent patient monitoring and a thorough understanding of its complex pharmacology.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for amiodarone is complex and varies significantly based on the route of administration (oral or intravenous), the specific indication, and the patient's clinical response and tolerance. For oral administration, a loading phase is typically required to achieve therapeutic plasma concentrations due to its large volume of distribution and long half-life. Oral loading doses commonly range from 800 to 1600 mg per day, administered in divided doses, for one to three weeks, or until an adequate therapeutic response is achieved or side effects become prominent. Following the loading phase, a maintenance dose is established, usually ranging from 100 to 400 mg once daily, with the lowest effective dose being preferred to mitigate toxicity risks. For intravenous administration, often used for acute management of life-threatening arrhythmias, a typical loading infusion involves 150 mg over 10 minutes, followed by 360 mg over the next 6 hours, and then a maintenance infusion of 540 mg over the remaining 18 hours (0.5 mg/min). Subsequent intravenous maintenance infusions may continue at 0.5 mg/min. Dose adjustments are crucial in patients with hepatic impairment and when co-administered with certain medications, requiring close clinical monitoring and consideration of drug-drug interactions, particularly due to its potent CYP450 inhibition. |
Safety & Warnings
Common Side Effects
- Amiodarone is associated with a wide spectrum of significant and potentially life-threatening side effects affecting multiple organ systems, attributed to its lipophilicity and prolonged elimination half-life.
- Pulmonary toxicity, manifesting as interstitial pneumonitis, fibrosis, or ARDS, is a major concern and can be fatal.
- Hepatic toxicity, ranging from elevated transaminases to severe hepatitis or cirrhosis, necessitates regular monitoring of liver function tests.
- Thyroid dysfunction is common, causing either hypothyroidism (more frequent) or hyperthyroidism, due to its iodine content and direct effects on thyroid hormone metabolism.
- Cardiovascular effects include bradycardia, heart block, and proarrhythmia (torsades de pointes), especially with intravenous use or electrolyte imbalances.
- Neurological effects can include peripheral neuropathy, ataxia, tremor, and dizziness.
- Ocular side effects commonly involve asymptomatic corneal microdeposits, but optic neuropathy leading to visual impairment or blindness is a rare but serious complication.
- Dermatologic reactions include photosensitivity (requiring sun protection) and, with long-term use, a characteristic blue-gray skin discoloration.
- Gastrointestinal disturbances like nausea, vomiting, and constipation are also frequently reported.
- Regular monitoring of pulmonary function, thyroid function, liver function, ECG, and ophthalmologic examinations are essential during amiodarone therapy to detect and manage these adverse effects proactively.
Serious Warnings
- Black Box Warning: Amiodarone carries a prominent FDA Black Box Warning highlighting its significant and potentially fatal toxicities. This warning emphasizes three primary areas of concern: 1. **Pulmonary Toxicity**: Amiodarone can cause severe and potentially fatal pulmonary toxicity, including interstitial pneumonitis, alveolar hemorrhage, and acute respiratory distress syndrome (ARDS). The risk increases with higher doses and duration of therapy, but can occur at any time. Symptoms such as dyspnea, non-productive cough, pleuritic chest pain, and fever warrant immediate investigation. Baseline and periodic pulmonary function tests and chest X-rays are crucial. 2. **Hepatotoxicity**: Severe hepatic toxicity, ranging from elevated liver enzymes to cirrhosis and fulminant hepatic failure, has been reported and can be fatal. Baseline and regular monitoring of liver function tests (LFTs) are essential. Therapy should be discontinued if transaminases persistently exceed twice the upper limit of normal or if signs of clinical hepatotoxicity develop. 3. **Proarrhythmic Effects**: Despite being an antiarrhythmic, amiodarone can exacerbate existing arrhythmias or induce new ones, including ventricular fibrillation and torsades de pointes, particularly in patients with pre-existing structural heart disease, electrolyte abnormalities, or concomitant use of other QT-prolonging drugs. The potential for these severe adverse effects underscores that amiodarone therapy should be initiated and managed only by physicians experienced in the treatment of life-threatening arrhythmias, ideally in a hospital setting for initial loading, and with appropriate monitoring capabilities. The long half-life of amiodarone means that toxicities can persist or emerge long after discontinuation of the drug.
- Amiodarone therapy requires careful patient selection and rigorous monitoring due to its complex pharmacokinetic profile and potential for serious adverse effects.
- Patients should undergo baseline and periodic evaluations including chest X-ray, pulmonary function tests, liver function tests, thyroid function tests, and ophthalmologic examinations.
- Significant drug interactions are common; amiodarone inhibits CYP450 enzymes (especially CYP2C9, CYP2D6, CYP3A4), increasing levels of co-administered drugs like warfarin (potentiating anticoagulant effect), digoxin (increasing digoxin levels), simvastatin (increasing risk of myopathy/rhabdomyolysis), and fentanyl.
- Dose adjustments for these and other medications are often necessary.
- Amiodarone can cause severe bradycardia or heart block, especially when co-administered with beta-blockers or calcium channel blockers, requiring careful ECG monitoring.
- Patients should be advised about photosensitivity and to use sun protection.
- Use in pregnancy is generally avoided due to potential fetal harm (thyroid dysfunction), and it is excreted into breast milk.
- Electrolyte imbalances, particularly hypokalemia and hypomagnesemia, must be corrected prior to and during therapy, as they can exacerbate proarrhythmic effects.
- In elderly patients, lower doses and slower titration may be warranted due to increased susceptibility to adverse effects and potential for polypharmacy, necessitating individualized treatment strategies.
How it Works (Mechanism of Action)
Amiodarone is classified primarily as a Class III antiarrhythmic agent, distinguishing itself through its unique multifaceted pharmacological profile that includes properties of all four Vaughan Williams classes. Its principal antiarrhythmic action stems from the prolongation of the action potential duration and refractory period in atrial and ventricular myocardial tissues, as well as in the AV node and accessory pathways. This is predominantly achieved by blocking potassium channels (IKr, IKs, IKATP, IKACh), thereby delaying repolarization. Beyond this, amiodarone exhibits Class I activity by blocking inactivated sodium channels, slowing the upstroke of the action potential. It also possesses Class II antiadrenergic effects by non-competitively blocking alpha- and beta-adrenergic receptors, leading to decreased heart rate and AV nodal conduction. Furthermore, it exerts Class IV calcium channel blocking activity, contributing to its effects on AV nodal conduction and peripheral vasodilation. This broad spectrum of electrophysiological effects contributes to its high efficacy in a wide range of supraventricular and ventricular arrhythmias, but also to its complex and extensive side effect profile, requiring careful clinical management.